12:00 AM
 | 
Mar 25, 2002
 |  BioCentury  |  Finance

What next for Biocompatibles?

Continuing its roller coaster month, Biocompatibles International plc (LSE:BII) fell 19.5p (18%) to 89p on Monday when 13.6 million shares were traded on news that the company had sold its cardiovascular stent business and drug-eluting stent programs to Abbott Laboratories (ABT) for £165 million ($234 million).

In the previous week, BII had leapt 34.5p (47%) to 108.5p on speculation about data from the CE Mark study of its Dextra phosphorylcholine (PC) coated stent. Three weeks back, BII had plummeted 78.5p (51%) to 74p on 20 million shares when the company stopped enrollment in its BRILLIANT II pivotal trial of BiodivYsio stent coated with batimastat (see...

Read the full 522 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >